MedTrace Logo

Basal Insulins - Pharmacodynamics

NCT00566124 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2007-12-03

No results posted yet for this study

Summary

To purpose of this study is to compare the pharmacodynamic properties of insulin detemir, insulin glargine and NPH insulin after a single subcutaneous injection.

Conditions

Interventions

DRUG

Insulin detemir

0.4 U/kg bw insulin detemir injected s.c. in the thigh.

DRUG

Insulin glargine

0.4 U/kg bw insulin glargine injected s.c. in the thigh

DRUG

Insulatard

0.4 U/kg bw NPH insulin injected s.c. in the thigh

Sponsors & Collaborators

  • The Danish Diabetes Association

    collaborator OTHER

  • The Institute of Experimental Clinical Research, University of Aarhus

    collaborator UNKNOWN

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Ole E. Schmitz, DMSc · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2005-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566124 on ClinicalTrials.gov